The co-infusion of angiotensin II during SIRT was also shown to significantly increase tumor targeting (tumor-to-normal-liver ratio × 3) by decreasing the healthy liver arterial flow, while the tumor arterial flow increased [57]. This evidence concerns the gene AGT and neoplasm.